Verndari Inc. With a mission to improve global health, Verndari develops and commercializes a novel intradermal vaccine delivery device to prevent serious infectious diseases. Their unique VaxiPatch™, a single-dose vaccination kit using intradermal microarray technology, offers numerous advantages, including dose sparing, improved efficacy, and pain-free delivery, making vaccine administration simpler.

What sets Verndari apart is their commitment to making vaccines more accessible by eliminating the need for cold chain shipping and storage, and enabling high-volume automated manufacturing. Their team, led by Chief Executive Officer Amy Van Prooyen and President John H. Brown, brings decades of experience in biopharmaceutical operations and executive management.

Guided by the expertise of Independent Chairman Jan A. Van Prooyen, a retired U. S.

Army Major General, Verndari is dedicated to revolutionizing vaccine delivery and building a brighter future through effective and efficient immunization